Get started
Author

Hyun Kyeong Yoo

Observed names: H K Yoo, H Yoo, Yoo, Hyun Kyeong
Observed institution: Celltrion (South Korea)
ORCID: 0000-0001-8924-7007
Observed ORCID: 0000-0001-8924-7007
OpenAlex ID: A5015448261
Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
2022 · Hyun Kyeong Yoo, Han Geul Byun, et al. · BMC Health Services Research · 17
PDF
Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
2021 · Han Geul Byun, Minyoung Jang, et al. · Applied Health Economics and Health Policy · 9
HPR41 Biosimilars: The Key to Lowering Access Barriers to Omalizumab Across Europe
2024 · S Yi, H Yoo, et al. · Value in Health · 1
P893 Budget impact analysis of introducing infliximab subcutaneous for the treatment of Inflammatory Bowel Disease in Latvia
2023 · H K Yoo, M Y Jang, et al. · Journal of Crohn s and Colitis
PDF
P888 Evaluating patient access to infliximab subcutaneous in inflammatory bowel disease
2023 · M Jang, H Yoo, et al. · Journal of Crohn s and Colitis
PDF
Works count: 7
Citation count: 27
H-index: 2
I10-index: 1
Year
Topic
Type